Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction

Dong Oh Kang, Yoonjee Park, Ji Hoon Seo, Myung Ho Jeong, Shung Chull Chae, Tae Hoon Ahn, Won Young Jang, Woohyeun Kim, Eun Jin Park, Byoung Geol Choi, Jin Oh Na, Cheol Ung Choi, Eung Ju Kim, Seung Woon Rha, Chang Gyu Park, Hong Seog Seo

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Background: Elevated high sensitivity C-reactive protein (hs-CRP) in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI) has prognostic value for future cardiovascular events. This study aimed to ascertain a valid prognostic time-period for predicting cardiovascular outcome based on baseline hs-CRP in AMI patients undergoing successful PCI on statin therapy. Methods: Overall, 4410 AMI patients were enrolled from the Korea Acute Myocardial Infarction-National Institutes of Health (KAMIR-NIH) registry. Participants were divided into groups according to cut-off values of baseline hs-CRP (1.0, 3.0, and 10.0 mg/L) and statin therapy intensity. The primary outcome was 36-month major adverse cardiovascular events (MACE), a composite of all-cause mortality, any myocardial infarction, and repeat revascularization. The secondary outcome was MACE developed 0–6, 6–12, and 12–36 months after AMI. Results: The overall incidence of 36-month MACE was significantly higher as baseline hs-CRP increased (by groups: 8.8% vs. 8.6% vs. 10.7% vs. 15.4%, log-rank p < 0.001). The prognostic effect of baseline hs-CRP was mostly confined to the first 6 months after AMI (0–6 months MACE by groups: 1.6% vs. 2.3% vs. 4.3% vs. 6.1%, log-rank p < 0.001) and attenuated in high-intensity statin users. Six months after AMI, this prognostic effect of baseline hs-CRP was remarkably reduced (6–12 month MACE by groups: 2.4% vs. 2.1% vs. 2.8% vs. 4.0%, log-rank p = 0.111, 12–36 month MACE by groups: 4.7% vs. 4.1% vs. 4.0% vs. 6.2%, log-rank p = 0.218); however, high-intensity statin treatment showed a consistent improvement in outcome. The observed time-dependent prognostic effects remained consistent following multivariate analysis. Conclusions: The prognostic impact of elevated hs-CRP at baseline was most evident during the first 6 months after AMI; however, the use of high-intensity statin persistently improved the clinical outcome even after the resolution of inflammatory reactions.

Original languageEnglish
Pages (from-to)74-83
Number of pages10
JournalJournal of Cardiology
Issue number1
Publication statusPublished - 2019 Jul


  • C-reactive protein
  • Coronary artery disease
  • Myocardial infarction
  • Percutaneous coronary intervention
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction'. Together they form a unique fingerprint.

Cite this